Amgen (AMGN) Spends $270 Million To Exit Osteporosis Pact With GlaxoSmithKline (GSK)
4/4/2014 6:10:45 AM
(Reuters) - Amgen Inc said it would end an agreement with GlaxoSmithKline Plc for the marketing of its osteoporosis drug in some regions outside the United States.
Amgen said it would take over the marketing of the drug, sold under the brand name Prolia, in most areas under the agreement, including the European Union, Switzerland, Norway, Russia and Mexico, by Dec. 31.
Help employers find you! Check out all the jobs and post your resume.
comments powered by